Overview

Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Status:
Completed

Trial end date:
2019-01-18

Target enrollment:

Participant gender:

Summary

A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin 5 mg and Empagliflozin 25 mg or Dapagliflozin 10 mg after Oral Administration in Healthy Male Adults

Phase:

Phase 1

Details

Lead Sponsor:

Dong-A ST Co., Ltd.

Treatments:

Dapagliflozin
Empagliflozin